New Zealand markets closed

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.6400-0.0300 (-1.12%)
At close: 04:00PM EST
2.6600 +0.02 (+0.76%)
After hours: 04:16PM EST

Poseida Therapeutics, Inc.

9390 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 779 3100

Full-time employees327

Key executives

NameTitlePayExercisedYear born
Mr. Mark J. Gergen J.D.President, CEO & Chairman920.74kN/A1963
Mr. Harry J. Leonhardt Esq., J.D.General Counsel, Chief Compliance Officer & Corporate Secretary630.23kN/A1957
Mr. Brent WarnerPresident of Gene Therapy835.93kN/A1984
Ms. Johanna M. Mylet CPAChief Financial OfficerN/AN/A1987
Mr. Loren WagnerSenior Vice President of Global OperationsN/AN/AN/A
Ms. Kristin MartinChief People & Administration OfficerN/AN/AN/A
Sarah ThailingSenior Director of Corporate Communications & IRN/AN/AN/A
Dr. Devon J. Shedlock Ph.D.Chief Scientific Officer of Cell TherapyN/AN/AN/A
Ms. Lisa PortaleSenior Vice President of Regulatory AffairsN/AN/AN/A
Dr. Jeffrey W. Winkelman J.D., Ph.D.Senior VP & Chief Patent CounselN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Corporate governance

Poseida Therapeutics, Inc.’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.